| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Cell Therapies | Renal/Genitourinary System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Cell Therapies | Renal/Genitourinary System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Cell Therapies | Renal/Genitourinary System |
Recent Updates
Recently added Catalysts
ProKidney Corp.$1.76
-0.04 (-2.22%)
B 62Pipeline Score Undervalued Biotech · Clinical
Market Cap
528.43 M
EPS
-0.53
P/E Ratio
-
Value Trade
1.48 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
226.00 K
R&D Expenses
33.84 M
Operating CF
-41.68 M
Total Assets
292.78 M
Total Liabilities
29.68 M
Equity
-1.02 B
D/E Ratio
12,345
1.74 %
Week
-17.84 %
1 Month
-20.09 %
3 Month
-15.87 %
6 Month
-82.59 %
5 Year
-82.59 %
All Time
Cash Data
Cash Position
265.43 M
Monthly Burn
13.89 M
Runway
17.5 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
936.95 K
52 Week Range
0.54 - 7.13
% held by Insiders
72.57 %
% held by Institutions
24.27 %
Enterprise Value
1.59 B
Total Shares
205.25 M
Short %
22.06 %
Float Shares
88.05 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for ProKidney Corp.
250Total events
8Upcoming
62Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 8
Event history 242
Jun 2, 2026
Jun 2026
◆Enrollment CompleterilparencelTrial
Enrollment completion for PROACT 1 accelerated approval analysis
chronic kidney disease with type 2 diabetessource ↗
Jun 2026
◆Enrollment MilestonerilparencelTrial
Complete enrollment for accelerated approval efficacy analysis (n=~360)
chronic kidney diseasesource ↗
Jan 14, 2026
◆Oral PresentationPresentation
ProKidney CEO to present at 44th Annual J.P. Morgan Healthcare Conference
Jan 2026
▲PublicationrilparencelPresentation
Phase 2 REGEN-007 results published in CJASN
chronic kidney disease with diabetessource ↗
2026
◆Oral PresentationrilparencelPresentation
Present results from mechanism of action studies at medical conferences
chronic kidney diseasesource ↗
2026
◆FDA Feedback ReceivedrilparencelFDA Meeting
Maintain dialogue with FDA under RMAT designation to prepare for BLA submission
chronic kidney diseasesource ↗
2026
▲Runway Guidance UpdateCorporate
Cash runway extended to mid-2026 through expected full enrollment of PROACT 1 and PROACT 2 Phase 3 studies
2026
◆Enrollment CompleterilparencelTrial
Expected full enrollment of PROACT 1 Phase 3 study
chronic kidney diseasesource ↗
2026
●BLA SubmissionREACTRegulatory Filing
Targeting BLA submission for REACT in 2026
diabetic chronic kidney diseasesource ↗
Drug Pipeline Intelligence
B62
Pipeline Score $5.8B
Pipeline ValueUndervalued
Valuation Signal1
Drugs Scored11.0x
rNPV / MCap Top 89%
Micro Cap (rank 101 of 911)
Percentile RankProKidney Corp. holds a solid B-grade pipeline (62/100), with $15.8B risk-adjusted pipeline value, led by Renal Autologous Cell Therapy in Type 2 Diabetes Mellitus (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Renal Autologous Cell Therapy Monoclonal antibody | Type 2 Diabetes Mellitus | Phase 3 | NCT02836574 | 61% | $15.8B | COMPLETED | 778 | - | - | Dec 1, 2023 | MODERATE_RISK | Aug 24, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
rilparencel AcceleratedRMAT | chronic kidney disease (CKD) | Phase 2 | 2026-05-15 | 4.6 mL/min/1.73m² improvement in the annual decline in eGFR slope Read More | ProKidney Reports First Quarter 2026 Financial Results and Business Highlights Read More | |
rilparencel AcceleratedRMAT | chronic kidney disease (CKD) | Phase 2 | 2026-05-15 | 4.6 mL/min/1.73m² improvement in the annual decline in eGFR slope Read More | ProKidney Reports First Quarter 2026 Financial Results and Business Highlights Read More | |
rilparencel AcceleratedRMAT | chronic kidney disease (CKD) | Phase 2 | 2026-05-15 | 4.6 mL/min/1.73m² improvement in the annual decline in eGFR slope Read More | ProKidney Reports First Quarter 2026 Financial Results and Business Highlights Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PROK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PROK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PROKProKidney Appoints Kenneth Locke as Chief Technical Officer
ProKidney Corp. has appointed Kenneth Locke as Chief Technical Officer to enhance its technical foundation as it prepares for a pivotal topline readout in Q2 2027. Locke brings extensive experience from Carisma Therapeutics and Celgene, where he led key manufacturing and regulatory functions. His leadership is expected to be vital as ProKidney advances its Phase 3 study for its autologous cell therapy targeting chronic kidney disease.
Read more →PROKProKidney Reports First Quarter 2026 Financial Results and Business Highlights
ProKidney Corp. reported its Q1 2026 financial results, highlighting progress in its Phase 3 PROACT 1 study for rilparencel, which is expected to complete enrollment by mid-2026. The company ended the quarter with $224.9 million in cash, supporting operations into mid-2027. Positive Phase 2 results were published, and FDA alignment on the accelerated approval pathway was confirmed.
Read more →PROKProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
ProKidney Corp. has appointed Greg Madison as Chief Commercial Officer to lead the company's commercial strategy as it advances the cell therapy rilparencel towards potential commercialization. Madison brings over two decades of experience in biopharma, having previously held leadership roles at Shield Therapeutics and Keryx Biopharmaceuticals. His expertise in nephrology will be crucial as ProKidney aims to address unmet needs in chronic kidney disease treatment.
Read more →PROKProKidney Reports Full Year 2025 Financial Results and Business Highlights
ProKidney Corp. reported its financial results for 2025, highlighting significant progress in its Phase 3 PROACT 1 study for rilparencel, with completion of enrollment expected by mid-2026. The company has aligned with the FDA on an accelerated approval pathway, using eGFR slope as a surrogate endpoint. Financially, ProKidney ended 2025 with $270 million in cash, supporting operations into mid-2027.
Read more →PROKThis presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney's actual results m
ProKidney is advancing its Phase 3 trial for Rilparencel, an autologous cell therapy for chronic kidney disease (CKD), aiming for potential accelerated FDA approval. The company has reported promising results from earlier trials, indicating that this treatment could stabilize kidney function. However, numerous risks hang over their operations, including potential disruptions following domestication to the U.S. and difficulties in obtaining regulatory approvals. Expectations for a Biologics License Application submission are set for 2H 2027, with several essential milestones planned for 2026.
Read more →PROK▲ +5.1%on this news
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
ProKidney Corp. announced that its CEO, Dr. Bruce Culleton, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company, which focuses on chronic kidney disease (CKD) treatment through cell therapy, is expected to engage in one-on-one meetings with investors during the event. ProKidney's lead product, rilparencel, is currently undergoing a Phase 3 clinical trial aimed at preserving kidney function in patients with advanced CKD and type 2 diabetes.
Read more →PROKProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
ProKidney Corp. reported its third quarter 2025 financial results, highlighting promising Phase 2 data for rilparencel in chronic kidney disease (CKD) patients. The FDA has confirmed that the eGFR slope can serve as a surrogate endpoint for accelerated approval. The company has sufficient cash to support operations through mid-2027, although it continues to incur significant losses.
Read more →PROKProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
ProKidney Corp. presented full results from the Phase 2 REGEN-007 trial of rilparencel at ASN Kidney Week 2025. The data indicates that rilparencel may preserve kidney function in patients with advanced chronic kidney disease (CKD) and diabetes. This trial supports the ongoing Phase 3 PROACT 1 study, which aims to evaluate the efficacy of rilparencel further.
Read more →PROKProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
ProKidney Corp. will participate in two significant healthcare conferences in November 2025. The Guggenheim Healthcare Innovation Conference will feature a fireside chat, while the Jefferies Global Healthcare Conference will include one-on-one meetings. These events aim to enhance investor engagement and showcase ProKidney's advancements in chronic kidney disease treatments.
Read more →PROK▲ +10.8%on this news
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
ProKidney Corp. announced the acceptance of two abstracts for presentation at the American Society of Nephrology's Kidney Week 2025. This includes a late-breaking poster on the Phase 2 REGEN-007 study results. The event will take place from November 6-9, 2025, in Houston, TX, showcasing advancements in cellular therapy for chronic kidney disease.
Read more →PROKProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
ProKidney Corp. will participate in the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference in September. The company's management team will engage in discussions about their innovative cellular therapies for chronic kidney disease. ProKidney's lead product, rilparencel, is currently in a Phase 3 study aimed at preserving kidney function.
Read more →PROKProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates • FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an accept
ProKidney Corp. has reported positive developments regarding their treatment rilparencel for chronic kidney disease (CKD) and diabetes. The FDA has confirmed that estimated glomerular filtration rate (eGFR) slope is an acceptable surrogate endpoint for accelerated approval, a decision made in a recent Type B meeting. In an encouraging announcement, the company revealed a 78% improvement in eGFR slope during Phase 2 REGEN-007 and has successfully enrolled more than half of the patients needed for their Phase 3 PROACT 1 study. However, the company also reported a $37 million net loss for Q2 2025, impacting their financial outlook.
Read more →PROK▼ -8.7%on this news
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
ProKidney Corp. has confirmed alignment with the FDA on the accelerated approval pathway for its cellular therapy, rilparencel, aimed at treating chronic kidney disease (CKD). The FDA has accepted the eGFR slope as a surrogate endpoint for a Biologics License Application (BLA). ProKidney anticipates topline data readout in Q2 2027 and has nearly completed patient enrollment for the analysis.
Read more →PROK▲ +16.4%on this news
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
ProKidney Corp. announced its participation in the H.C. Wainwright 4th Annual Kidney Virtual Conference. Senior management will engage in discussions about their advancements in cellular therapeutics for chronic kidney disease. The company's lead product, rilparencel, is under evaluation in Phase 2 and Phase 3 studies and has received FDA's RMAT designation.
Read more →PROK▲ +515%on this news· ran to +649% by day 3shared move
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
ProKidney Corp. announced positive topline results from the Phase 2 REGEN-007 trial of rilparencel in patients with chronic kidney disease and diabetes. The trial demonstrated a statistically significant improvement in the estimated glomerular filtration rate (eGFR) slope. The company plans to present full results at the ASN 2025 Kidney Week and has an upcoming FDA Type B meeting to discuss accelerated approval pathways.
Read more →PROKProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
ProKidney Corp. has successfully completed its domestication from the Cayman Islands to Delaware, effective July 1, 2025. This change was approved by shareholders at the Annual General Meeting on May 29, 2025. The company's Class A and Class B shares will now trade under the same symbols on Nasdaq, with no expected impact on operations.
Read more →PROKProKidney Reports First Quarter 2025 Financial Results and Business Highlights • Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025 • FDA previously confirmed in a Q4 2024 Type B meet
ProKidney Corp. has reported its financial results for the first quarter of 2025, highlighting a cash position of $328.5 million, which supports operations until mid-2027. Key upcoming milestones include the anticipated full data from the Phase 2 REGEN-007 study in Q2 2025 and a regulatory update regarding the accelerated approval pathway for rilparencel. The company reported a net loss before noncontrolling interest of $38.0 million, a slight increase from the previous year. The focus remains on addressing chronic kidney disease through their innovative treatments involving rilparencel.
Read more →PROK▲ +5.7%on this news
ProKidney Reports Full Year 2024 Financial Results and Business Highlights • Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel's path to market in the U.S., th
ProKidney Corp. announced its full-year financial results for 2024, highlighting significant advances in its clinical programs, particularly for rilparencel, aimed at treating chronic kidney disease in diabetic patients. The company refined its Phase 3 program and secured $140 million in equity funding to support its financial needs through mid-2027. ProKidney received confirmation from the FDA regarding the availability of an accelerated approval pathway for rilparencel and anticipates further data releases in 2025 from its clinical studies. Despite these advancements, the company reported an increase in net loss and rising research and development expenses.
Read more →PROKProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ProKidney Corp. announced that CEO Bruce Culleton will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The presentation will highlight their first-in-class cell therapy candidate, rilparencel, which aims to improve kidney function in diabetic patients. ProKidney's management will also conduct one-on-one meetings during the conference to engage with potential investors and stakeholders.
Read more →PROKProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
ProKidney Corp. will participate in the Evercore HealthCONx and Citi Global Healthcare Conferences in December. Senior management will engage in a fireside chat and one-on-one meetings to discuss their lead cell therapy candidate, rilparencel, which aims to treat chronic kidney disease. The participation in these events highlights ProKidney's focus on advancing its innovative treatment solutions.
Read more →PROKProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting • FDA confirmed in a recent FDA Type B meeting under RMAT desig
ProKidney Corp. reported its third-quarter financial results for 2024, highlighting a successful FDA Type B meeting where the FDA confirmed that the PROACT 1 Phase 3 study could be sufficient for a Biologics License Application submission for rilparencel. The FDA also indicated that an accelerated approval pathway might be possible by using eGFR slope as a surrogate endpoint. The company ended the quarter with $406.8 million in cash, providing operational support into 2027. Additionally, ProKidney presented five posters at the ASN Kidney Week, including updates on rilparencel's mechanism of action.
Read more →PROKProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
ProKidney Corp. will participate in two significant healthcare conferences in November, namely the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference. During these events, the management team will engage in fireside chats and hold one-on-one meetings with investors. ProKidney is known for its innovative autologous cellular therapy candidate, rilparencel, which is currently in Phase 2 and Phase 3 studies for chronic kidney disease. The company emphasizes its pioneering role in developing therapies for kidney diseases. The webcasts for these conferences will be available on ProKidney's website.
Read more →PROKProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
ProKidney Corp. announced that it will present five abstracts at the American Society of Nephrology’s Kidney Week 2024, scheduled from October 23-27 in San Diego, CA. Among these, a late-breaking clinical trial for Rilparencel, an autologous cell therapy for chronic kidney disease patients with diabetes, will be highlighted. The presentations will showcase various detailed studies on Rilparencel's effects on kidney function and related biological pathways. Additional information and the abstracts will be made available on the company's website post-event.
Read more →PROKProKidney to Participate in the UBS Virtual Organ Restoration Day
ProKidney Corp. announced its participation in the UBS Virtual Organ Restoration Day scheduled for October 15, 2024. Senior management will be involved in a fireside chat, discussing the company's innovations in cell therapy for chronic kidney disease. ProKidney's lead product candidate, rilparencel, is under evaluation in Phase 2 and Phase 3 studies, having received RMAT designation from the FDA. The event will also include one-on-one meetings for interested investors.
Read more →PROKProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
ProKidney Corp. has announced strategic updates to its Phase 3 program for rilparencel, aiming to streamline its path to U.S. approval by focusing exclusively on the PROACT 1 trial. This decision follows consultations with regulatory experts, concluding that the PROACT 2 trial, which catered to international enrollment, is unnecessary for initial registration in the U.S. The company anticipates that these modifications will result in topline data by Q3 2027 and reduce operational costs significantl. ProKidney maintains optimism about rilparencel's potential to meet the high unmet needs in chronic kidney disease management.
Read more →PROK▼ -7.5%on this news
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
ProKidney Corp. will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 5, 2024. Senior management will engage in a fireside chat format, which will also be streamed live via webcast. Following the chat, there will be opportunities for one-on-one meetings with investors. ProKidney is noted for its development of innovative cellular therapies aimed at treating chronic kidney disease.
Read more →PROKProKidney Reports Business Updates and Second Quarter 2024 Financial Results • Reported interim REGEN-007 data that demonstrate rilparencel's potential to preserve kidney function in patients with diabetes and adv
ProKidney Corp. reported positive interim data from its REGEN-007 study, indicating that rilparencel may preserve kidney function in patients with diabetes and advanced chronic kidney disease (CKD). The company has restarted manufacturing and resumed Phase 3 trials following a $140 million public offering. As of June 30, 2024, ProKidney ended the quarter with $431.5 million in cash equivalents, supporting funding for operations through the anticipated completion of Phase 3 enrollment in mid-2026.
Read more →PROK▲ +7%on this news
ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
ProKidney Corp. has successfully closed a $140 million public offering of its Class A ordinary shares, including a concurrent registered direct offering. The funds raised will extend the company's cash runway to mid-2026, allowing for further development of its lead product candidate, rilparencel, which aims to preserve kidney function in high-risk diabetic patients. The successful closure of these offerings marks a significant milestone in ProKidney's efforts to advance treatments for chronic kidney disease. Key financial firms managed the offerings, reflecting investor confidence in the company.
Read more →PROK▼ -19.9%on this news
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering WINSTON-SALEM, N.C.
ProKidney Corp. has announced the pricing of a $130 million public offering of its Class A ordinary shares, with an additional option for underwriters to purchase more shares. The offerings are intended to finance clinical trials and ongoing development of its cellular therapies for chronic kidney disease. The closing of the offerings is anticipated on June 13, 2024, pending customary conditions, creating opportunities for enhanced financial backing and progress in its product pipeline.
Read more →PROK▼ -5.3%on this news· ran to -24% by day 1shared move
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
ProKidney Corp. announced a proposed public offering of Class A ordinary shares and a concurrent registered direct offering, aiming to raise $125 million. The proceeds will be allocated to clinical trials, research and development, and commercial activities. While there is investor interest from significant stakeholders, the commitments are not binding, leaving some uncertainty about the final sale. The company must also navigate market conditions that could affect the offerings' completion.
Read more →PROK▼ -5.3%on this news· ran to -24% by day 1shared move
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 months Safety profil
ProKidney Corp. announced positive interim results from its Phase 2 REGEN-007 trial, focusing on its renal autologous cell therapy rilparencel for chronic kidney disease (CKD) resulting from diabetes. The data indicated an 18-month stabilization of kidney function in patients receiving treatment, with no observed serious adverse events. This announcement marks a significant operational development, with manufacturing restarted and Phase 3 clinical studies resumed. A live webcast will be held to discuss these interim findings and future directions.
Read more →PROK▲ +6.7%on this news· ran to -18% by day 3
RMCL-002 Final Analysis Developing Solutions for Dialysis Prevention May 2024 This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigatio
The final analysis of RMCL-002 highlights promising results for ProKidney's treatment aimed at preventing dialysis in kidney disease patients. The study indicates that the treatment may preserve kidney function for up to 30 months across various patient groups. Overall, the injections were well tolerated and showed a safety profile similar to kidney biopsies. However, the company warns that many factors could impact future performance and regulatory approvals, adding to the risks surrounding its development and commercialization efforts.
Read more →PROK▲ +6.7%on this news· ran to -18% by day 3
ProKidney to Participate in the Jefferies Global Healthcare Conference
ProKidney Corp. will participate in the Jefferies Global Healthcare Conference from June 4 to 6, 2024, in New York. The management team will conduct one-on-one meetings with interested investors to discuss company developments and opportunities. ProKidney's lead product, rilparencel, aims to preserve kidney function in high-risk diabetic patients and is currently in Phase 3 clinical trials with encouraging regulatory support. This event marks a significant occasion for the company to enhance its investor relations and showcase its innovative therapies.
Read more →PROKProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
ProKidney Corp. announced a virtual KOL event scheduled for May 28, 2024, aimed at discussing the current treatment landscape of chronic kidney disease (CKD) caused by diabetes. The event will feature experts Steven G. Coca and Arnold L. Silva, who will highlight the importance of preserving kidney function in affected patients. Moreover, the final data from the Phase 2 RMCL-002 trial of ProKidney's lead candidate, rilparencel, will be presented during the event.
Read more →PROK▲ +7.7%on this news· ran to +50% by day 3
ProKidney Reports Business Updates and First Quarter 2024 Financial Results • Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Associatio
ProKidney Corp. has reported business updates and financial results for Q1 2024, highlighting significant developments such as the anticipated presentation of RMCL-002 Phase 2 trial results at the ERA Congress. The company is on track to resume its PROACT 1 Phase 3 trial and commence PROACT 2, alongside sharing interim results from the REGEN-007 Phase 2 trial. Financially, ProKidney ended the quarter with $329 million in cash, enabling operational plans through Q4 2025, albeit with a net loss of $35.3 million. Recent leadership appointments aim to bolster the company's clinical and operational capabilities.
Read more →PROKProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process d
ProKidney Corp. has appointed Dr. Ulrich Ernst as Executive Vice President of Technical Operations and Mr. Lucio Tozzi as Senior Vice President of Global Clinical Operations. Both leaders bring extensive experience to strengthen the company's efforts in clinical and technical operations. These appointments are strategic as ProKidney advances its Phase 3 program for its candidate, rilparencel, aimed at chronic kidney disease. Their expertise is expected to support future commercialization and the execution of complex clinical trials.
Read more →PROK▼ -6.2%on this newsshared move
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights WINSTON-SALEM, N.C.
ProKidney Corp. announced its full year 2023 financial results, highlighting the promising interim data for its lead product candidate, rilparencel, which shows potential in preserving kidney function for patients with type 2 diabetes and advanced CKD. The company appointed Dr. Bruce Culleton as CEO and Nikhil Pereira-Kamath as CBO, strengthening its leadership team. Despite a net loss of $135.4 million, ProKidney maintains a robust cash position of $363 million, enabling continued operations into late 2025. However, ongoing amendments related to clinical trials may impact enrollment timelines and production processes.
Read more →PROKProKidney to Participate in Jefferies Biotech on the Bay Summit
ProKidney Corp. will participate in the Jefferies Biotech on the Bay Summit on March 12-13, 2024, where its management team will hold one-on-one meetings with investors. The company focuses on chronic kidney disease and is advancing its lead product candidate, REACT® (Renal Autologous Cell Therapy), which has been designated as a Regenerative Medicine Advanced Therapy (RMAT). Launched in January 2022, the Phase 3 clinical program aims to evaluate the treatment's effectiveness in preserving kidney function for diabetic patients at risk of kidney failure.
Read more →PROK▼ -10.1%on this news
Corporate Presentation January 2024 Developing Solutions for Dialysis Prevention REACT [REnal Autologous Cell Therapy] Forward-looking Statements This presentation includes "forward-looking statements" within the meaning
ProKidney is advancing its REACT (REnal Autologous Cell Therapy) program, which aims to preserve kidney function in patients with diabetic kidney disease. The therapy is currently undergoing Phase 3 trials and shows promise in potentially delaying the need for dialysis. However, ProKidney has cautioned that actual results may differ from projections due to various market and regulatory challenges. The company remains focused on innovative solutions for chronic kidney disease, highlighting the urgency given the high prevalence of the condition.
Read more →PROK▼ -10.2%on this news
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
ProKidney Corp. has appointed Nikhil Pereira-Kamath as its new Chief Business Officer, taking over global responsibilities for commercial strategy and business development. Pereira-Kamath brings over a decade of experience, including leadership roles at Africa Healthcare Network and expertise in healthcare finance. His appointment comes as ProKidney advances through late-stage clinical development of its autologous cell therapy, REACT®, which aims to preserve kidney function in patients at risk of kidney failure. The company's progress is backed by Regenerative Medicine Advanced Therapy designation and FDA guidance.
Read more →PROK▲ +5.7%on this news
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
ProKidney Corp. has announced its participation in the 6th Annual Evercore ISI HEALTHCONx Conference scheduled for November 28-30, 2023, in Miami, Florida. Management will be available for a fireside chat to discuss the company's innovative cellular therapies aimed at preserving kidney function in patients with chronic kidney disease. The lead product candidate, REACT, has received special designations from regulatory bodies, bolstering its Phase 3 clinical program launched earlier this year.
Read more →PROK▼ -5%on this news· ran to -24% by day 3
ProKidney Reports Third Quarter Financial Results
ProKidney Corp. reported its financial results for Q3 2023, highlighting nearly $400 million in cash reserves. The company continues to progress in its Phase 2 and Phase 3 clinical trials for chronic kidney disease treatments. Notably, ProKidney's lead product candidate, REACT, has received Regenerative Medicine Advanced Therapy designation. However, the financial results show an increase in net loss and rising R&D expenses, signaling a significant investment in its clinical development efforts.
Read more →PROK▼ -5%on this news· ran to -24% by day 3
RMCL-002 Interim Results & Updates
ProKidney's RMCL-002 interim results from the REACT Phase 2 study show promising potential for preserving kidney function in diabetic patients with advanced kidney disease. The findings could lead to advancements in treatment options for chronic kidney disease (CKD), addressing a significant unmet need in the patient population. The clinical program aims to delay the progression to dialysis, which is crucial given the rising burden of CKD among U.S. adults. Further studies and developments will continue to assess the therapy's efficacy and market impact.
Read more →PROK▼ -5%on this news· ran to -24% by day 3
ProKidney Reports Third Quarter Financial Results WINSTON-SALEM, N.C.
ProKidney Corp. reported its third-quarter financial results, announcing a liquidity position of approximately $396.3 million as of September 30, 2023. The company is well-capitalized to advance its Phase 2 and Phase 3 clinical trials for chronic kidney disease treatments, particularly its lead product, REACT. However, R&D expenses surged, contributing to a net loss before noncontrolling interest of $42 million, highlighting a potential concern for sustainability as it aims to bring innovative therapies to market.
Read more →PROKProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT ) for Diabetic CKD and Provides Corporate Updates
ProKidney Corp. announced positive interim results from its RMCL-002 Phase 2 trial, demonstrating REACT®'s efficacy in preserving kidney function in diabetic CKD patients. The company plans to focus its Phase 3 program on high-risk CKD patients while temporarily pausing manufacturing for quality improvements. Dr. Bruce Culleton has been appointed as the new CEO, bringing significant experience to lead the company's pivotal trials. ProKidney is well funded, with sufficient capital to support operations into the fourth quarter of 2025.
Read more →PROK▲ +12.3%on this news
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
ProKidney Corp. has announced that four of its abstracts have been selected for presentation at the American Society of Nephrology’s Kidney Week 2023. These presentations will focus on the company's REACT® cellular therapeutic for chronic kidney disease and its mechanisms of action. The event will take place November 2-5, 2023, in Philadelphia, PA, where attendees can learn more about REACT® at the ProKidney booth. Following the presentations, materials will be available on ProKidney's website.
Read more →PROKPROKIDNEY. A Step Closer to Potential Dialysis Prevention REACT [REnal Autologous Cell Therapy] Forward-looking Statements This presentation includes “forward-looking statements” within the meaning of the &
ProKidney is advancing its REACT cell therapy aimed at preventing dialysis for patients with Chronic Kidney Disease (CKD). The company is in its Phase 3 clinical program and has received guidance from both the FDA and EMA, aiming for potential regulatory approvals and market entry by 2026. The therapy utilizes the patient’s own kidney cells and targets the preservation of kidney function, addressing a significant public health issue as millions face the transition to dialysis each year. However, the company faces several risks related to regulatory approvals and financial sustainability.
Read more →PROKProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
ProKidney Corp. (Nasdaq: PROK) announced that Dr. Tim Bertram, its CEO, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference scheduled for September 11-14, 2023. The session will be available via live webcast on ProKidney’s investor relations website. The company specializes in cellular therapeutics focused on preserving kidney function in chronic kidney disease patients, with its lead candidate, REACT®, having advanced to a Phase 3 clinical program. ProKidney aims to engage investors and showcase its innovative approach to treatment at the conference.
Read more →PROKProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights WINSTON-SALEM, N.C. –
ProKidney Corp. reported its second quarter financial results for 2023, revealing advances in its REACT development programs aimed at treating chronic kidney disease. The company's CEO highlighted expectations for interim data from key clinical studies and emphasized a sizable investment into a new facility to enhance manufacturing capabilities. Financial results showed a net loss of $34.8 million for the quarter, up from $22.1 million the previous year, amidst rising R&D expenses. ProKidney aims to advance towards regulatory approvals and commercial launch by the end of 2023.
Read more →PROKProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC WINSTON-SALEM, N.C.
ProKidney Corp. has announced the successful acquisition of a 210,000 square foot manufacturing facility in Greensboro, North Carolina, for approximately $25.5 million. The company plans to invest in this facility through 2028 to prepare for commercial-scale production of its proprietary REACT therapy, which is currently in Phase 3 development. In addition to the purchase, local government has approved incentive packages that could provide up to $33.7 million in tax credits based on performance milestones. This strategic move supports ProKidney's mission to preserve kidney function in patients with chronic kidney disease.
Read more →PROK▲ +6.7%on this newsshared move
ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization
ProKidney Corp. has appointed Dr. Bruce Culleton as Executive Vice President of Clinical Development and Commercialization. Dr. Culleton joins with over 20 years of experience in the kidney health sector, having previously worked with CVS Kidney Care and Becton Dickinson. His appointment is seen as pivotal as ProKidney advances its lead product candidate, REACT, through its Phase 3 clinical program towards a potential commercial launch. The company anticipates initial interim data in late 2024, marking a significant milestone in its mission to improve the lives of chronic kidney disease patients.
Read more →PROKProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC WINSTON-SALEM, N.C.
ProKidney Corp. has announced the acquisition of a 210,000 square foot manufacturing facility in Greensboro, NC, to advance its commercial manufacturing of REACT, an innovative cellular therapy for chronic kidney disease, currently in Phase 3 development. The purchase, amounting to approximately $25.5 million, is set to close by the end of June 2023, pending customary conditions. ProKidney plans to invest further in the facility until 2028, in anticipation of a potential FDA approval and launch of REACT in 2026. The acquisition is part of the company's strategic manufacturing expansion to meet projected market demand and job creation commitments in the region.
Read more →PROK▼ -7.7%on this news
ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference
ProKidney Corp. (Nasdaq: PROK) has announced its participation in the Jefferies Healthcare Conference, which will take place in New York from June 7 to 9, 2023. CEO Dr. Tim Bertram is scheduled to engage in a fireside chat on June 8, to discuss the company's advancements in cellular therapeutics for chronic kidney disease (CKD). ProKidney's REACT therapy, designed for late-stage CKD patients, has received regulatory designations highlighting its potential impact on preserving kidney function. The conference represents a key opportunity for the company to connect with investors and showcase its pipelines.
Read more →PROKProKidney Reports First Quarter Financial Results and Recent Corporate Highlights WINSTON-SALEM, N.C. –
ProKidney Corp. has reported positive advancements in its clinical trials and financial results for the first quarter of 2023. The company is advancing the Phase 3 development of its REACT therapy aimed at chronic kidney disease. Enrollment has been completed for its REGEN-007 Phase 2 study, with initial data expected later this year. ProKidney maintains a solid financial position with about $464 million available, despite a reported net loss.
Read more →PROKProKidney to Present at the BofA Securities Health Care Conference 2023
ProKidney Corp. announced that its CEO, Dr. Tim Bertram, will present at the BofA Securities Health Care Conference 2023 in Las Vegas on May 9, 2023. The company focuses on advanced cellular therapeutics for chronic kidney disease (CKD) and aims to provide innovative treatment options. ProKidney's lead product, REACT, is designed to preserve kidney function in patients at high risk of kidney failure and has received special regulatory designation to support its Phase 3 clinical trials. The event may provide an opportunity for investors to gain insights into the company's future direction and growth potential.
Read more →PROK▼ -7.4%on this news
ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights WINSTON-SALEM, N.C. –
ProKidney Corp. announced its fourth quarter financial results and highlighted significant progress in its clinical trials for the REACT therapy targeting chronic kidney disease. The company's pivotal Phase 3 trials are advancing, with initial data from the proact1 study expected by the end of 2024. Additionally, ProKidney has strengthened its financial position, having raised over $500 million from PIPE financing. Despite reporting a net loss during the quarter, the company is well-positioned for upcoming milestones in 2023.
Read more →PROKForward-looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. P
ProKidney's presentation highlights their forward-looking statements regarding the development of REACT, a cell therapy aimed at treating Chronic Kidney Disease (CKD). The therapy utilizes autologous kidney cells and is currently in Phase 3 clinical trials with support from regulatory authorities. The company projects a commercial launch by the end of 2026, with an expected market expansion in the treatment of CKD and related conditions. However, the presentation also emphasizes the uncertainties and risks associated with the biotechnology industry that may impact future results.
Read more →PROKProKidney to Participate in TD Cowen’s 43rd Annual Health Care Conference
ProKidney Corp. announced its participation in TD Cowen's 43rd Annual Health Care Conference, scheduled for March 7, 2023. CEO Dr. Tim Bertram will present the company's innovative approach to treating chronic kidney disease, particularly their patented REACT™ therapy. This therapy aims to stabilize or improve kidney function in patients suffering from late-stage CKD and has received supportive regulatory designations. The event is expected to facilitate engagements with investors and enhance ProKidney's presence in the healthcare market.
Read more →PROK▲ +9.6%on this news· ran to +20% by day 3
PROKIDNEY A Step Closer to Potential Dialysis Prevention REACT [REnal Autologous Cell Therapy] Forward-looking Statements This presentation includes “forward-looking statements” within the meaning of the &#
ProKidney advances its REACT (REnal Autologous Cell Therapy) for Chronic Kidney Disease (CKD) with promising clinical results and FDA guidance. The therapy aims to prevent dialysis for millions of patients, addressing a significant healthcare crisis. As the company prepares for a commercial launch in late 2026, ongoing trials are expected to provide further insights into the therapy’s effectiveness and market potential. ProKidney has secured funding to support these initiatives, but faces challenges related to competition and regulatory hurdles.
Read more →PROK▲ +9.6%on this news· ran to +20% by day 3
ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease - Article published online in the Journal of Blood Purification ; t
ProKidney Corp. announced the publication of its Phase 2 clinical trial design for REACT, aimed at treating late-stage diabetes-related chronic kidney disease. This multicenter trial showcased the potential of REACT to delay dialysis requirements for patients with severely compromised kidney function. Published in the Journal of Blood Purification, the study highlights promising data, including instances of preserved kidney function among participants. However, the study also notes serious adverse events, underscoring the risks involved in such a high-risk patient population.
Read more →PROKProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference
WINSTON-SALEM, N.C., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will present at
Read more →PROKProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights WINSTON-SALEM, N.C. –
ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights WINSTON-SALEM, N.C. November 14, 2022 ProKidney Corp. (Nasdaq: PROK) ( ProKidney or the Company ), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease
Read more →PROK▲ +6.9%on this newsshared move
ProKidney to Participate in Upcoming Investor Conferences
WINSTON-SALEM, N.C., Nov. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will participat
Read more →PROKProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease
WINSTON-SALEM, N.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the allowance of the proact 1 (REGEN-006) Phase 3 study protoc
Read more →PROKProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2022
- Company will present five posters discussing REACT and chronic kidney disease during the ASN Annual Meeting, November 3 - 6, 2022 - Investor and analyst scientific briefing to be hosted in Orlando, FL on November 3, 2022 WINSTON-SALEM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) --
Read more →PROKProKidney to Present at the Jefferies Cell and Genetic Medicine Summit
WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, w
Read more →PROKProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
WINSTON-SALEM, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, w
Read more →PROKRenal Autologous Cell Therapy September 2022 A Step Closer to Potential Dialysis Prevention ProKidney Corp. Nasdaq: PROK Forward-looking Statements This presentation includes “forward-looking statements” wi
Renal Autologous Cell Therapy September 2022 A Step Closer to Potential Dialysis Prevention ProKidney Corp. Nasdaq: PROK Forward-looking Statements This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Li
Read more →PROK▲ +12.3%on this news
ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations
Brings nearly 20 years of investor relations and corporate communications experience to ProKidney WINSTON-SALEM, N. C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic
Read more →PROK▲ +7.5%on this news
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., A
Read more →PROK▲ +7.5%on this news
ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update Completed business combination with Social Capital Suvretta Holdings, III WINSTON-SALEM, N.C. –
ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update Completed business combination with Social Capital Suvretta Holdings, III WINSTON-SALEM, N.C. August 11, 2022 ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III or SCS )
Read more →PROKProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
WINSTON-SALEM, NC, July 20, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on Chronic Kidney Disease (CKD), announces the appointment of nephrologist Kerry Cooper, M.D. as
Read more →PROKRevolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III ProKidney Class A ordinary shares to begin trading
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III Winston-Salem, NC & Palo Alto, CA July 12, 2022 ProKidney LP ( ProKidney ), a leading late clinical-stage ce
Read more →PROKSocial Capital Suvretta Holdings Corp. III Announces Reconvened Extraordinary General Meeting of Shareholders
Social Capital Suvretta Holdings Corp. III Announces Reconvened Extraordinary General Meeting of Shareholders Calif., July 8, 2022 /Business Wire/ Social Capital Suvretta Holdings Corp. III ( SCS ) today announced that it will reconvene the Extraordinary General Meeting of its
Read more →PROKProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease
WINSTON-SALEM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of end-stage renal disease (ESRD) requiring dialysis or transplant,
Read more →PROKProKidney Announces Manufacturing Efficiency Initiatives and Supply Chain Streamlining Expected to Reduce REACT™ Manufacturing Costs
WINSTON-SALEM, N.C., June 15, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announced an update on manufacturing efficiency and supply chain streamlining i
Read more →PROKSOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Financial Statement: Balance Sheet (as restated) F-3 Notes to Financial Statement F-4 F-
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Financial Statement: Balance Sheet (as restated) F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUN
Read more →PROKProKidney to present at upcoming investor conferences
WINSTON-SALEM, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of both end-stage renal disease (ESRD) and the need for dialysis, tod
Read more →PROKProKidney highlights key registrational program elements supporting advancement of REACT
WINSTON-SALEM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of both end-stage renal disease (ESRD) and the need for dialysis, tod
Read more →PROKProKidney Appoints Libbie Parker McKenzie, MD, FASN as Chief Medical Officer
WINSTON-SALEM, N.C., April 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and prevention of both end-stage renal disease (ESRD) and the need for dialysis, today
Read more →PROKRenal Autologous Cell Therapy A Step Closer to Potential Dialysis Prevention
Dialysis Prevention April 28, 2022 1 Disclaimer General Disclaimer This investor presentation (this "Presentation") was prepared by Social Capital Suvretta Holdings Corp. III (the "SPAC" or "DNAC") and ProKidney, LLC (the "Company" or "ProKidney"). This Presentation is intended
Read more →PROKProKidney and Social Capital Suvretta Holdings Corp. III (“SCS”) to Host Analyst and Investor Day on April 28, 2022
WINSTON-SALEM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney) is a leading Phase 3 clinical-stage cellular therapeutics company with Regenerative Medicine Advanced Therapy (RMAT) Designation that has the goal of delaying chronic kidney disease (CKD), preventing
Read more →PROKProKidney confirms Phase 3 program for autologous kidney cell therapy REACT
WINSTON-SALEM, N.C., April 12, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announced the updated design for its REACT® Phase 3 program. REGEN-006 and RE
Read more →PROKProKidney Appoints Todd C. Girolamo as General Counsel
WINSTON-SALEM, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevention of end-stage renal disease (ESRD) and need for dialysis, today announced t
Read more →PROKProKidney to Present REACT at 4th Annual CKD Summit
Presentation to include data on Mechanism of Action, clinical trials to-date and current regulatory status WINSTON-SALEM, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic ki
Read more →PROKProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT Autologous Cell Therapy for Treatment of Chronic Kidney Disease
Article published online in American Journal of Nephrology; to be included in future print edition WINSTON SALEM, N.C., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (“CKD”),
Read more →PROKRevolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III ProKidney offers a first-of-its-kind, patented diseas
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III Winston-Salem, NC & Palo Alto, CA January 18, 2022 ProKidney LP ( ProKidney ), a leading clinical-stage cellul
Read more →PROKSOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Financial Statement: Balance Sheet F-3 Notes to Financial Statement F-4 F-1 REPORT OF IN
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Financial Statement: Balance Sheet F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To
Read more →PROKSocial Capital Suvretta Holdings Corp. III Announces Pricing of Upsized $220,000,000 Initial Public Offering
Social Capital Suvretta Holdings Corp. III Announces Pricing of Upsized $220,000,000 Initial Public Offering PALO ALTO, Calif., Jun. 30, 2021 /Business Wire/ Social Capital Suvretta Holdings Corp. III (the Company ) announced today that it has priced its upsized initial public
Read more →Competitive Position
How PROK ranks across every disease it competes inCompetitive Position is a premium feature
See how PROK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial